## Jonathan E Schoenhals

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6587537/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. Cancer Research, 2017, 77, 839-850.	0.9	195
2	Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment. Frontiers in Immunology, 2019, 10, 193.	4.8	105
3	Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. , 2020, 8, e000537.		105
4	Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy, 2015, 7, 967-980.	2.0	83
5	Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 367-375.	0.8	65
6	Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses. Clinical Cancer Research, 2019, 25, 7576-7584.	7.0	51
7	Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells. Cancer Letters, 2018, 431, 54-63.	7.2	50
8	Radiation therapy and immunotherapy: what is the optimal timing or sequencing?. Immunotherapy, 2018, 10, 299-316.	2.0	49
9	Anti-glucocorticoid-induced Tumor Necrosis Factor–Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects. Frontiers in Immunology, 2018, 9, 2170.	4.8	48
10	Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti–PD1-Resistant Lung Tumor Model. Clinical Cancer Research, 2018, 24, 5735-5743.	7.0	48
11	IDO1 Inhibition Overcomes Radiation-Induced "Rebound Immune Suppression―by Reducing Numbers of IDO1-Expressing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. International Journal of Radiation Oncology Biology Physics, 2019, 104, 903-912.	0.8	39
12	Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. Cancer Journal (Sudbury, Mass ), 2016, 22, 257-266.	2.0	38
13	Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy. Cancer Journal (Sudbury, Mass ), 2016, 22, 130-137.	2.0	37
14	Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation. Translational Lung Cancer Research, 2007, 6, 148-158.	2.8	33
15	Bone morphogenetic protein 7 promotes resistance to immunotherapy. Nature Communications, 2020, 11, 4840.	12.8	25
16	Genome Sequences of 19 Novel Erwinia amylovora Bacteriophages. Genome Announcements, 2017, 5, .	0.8	22
17	Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma. Advances in Radiation Oncology, 2021, 6, 100692.	1.2	18
18	Optimizing Radiotherapy with Immunotherapeutic Approaches. Advances in Experimental Medicine and Biology, 2017, 995, 53-71.	1.6	10

#	Article	IF	CITATIONS
19	Translational Research and Immunotherapy in Lung Cancer. , 2016, , 255-296.		0
20	Outcomes of stereotactic ablative radiotherapy for extra-cranial oligo-metastatic renal cell cancer Journal of Clinical Oncology, 2019, 37, 599-599.	1.6	0
21	DC-HIL/Gpnmb checkpoint blockade as a synergistic combination for stereotactic ablative radiation (SAbR) Journal of Clinical Oncology, 2019, 37, e14129-e14129.	1.6	0